

Development and validation of a method for quantification of 15 antiviral drugs against influenza in poultry muscle using LC-MS/MS

CIFSQ 2021- 28/10/2021


Clément Douillet, Martin Danaher, Christopher Elliott

Index

- Introduction: avian influenza and antiviral drugs
- Method development
 - LC-MS/MS optimisation
 - Sample preparation development
- Method performance, validation and analytes stability
- Occurrence and conclusion


Influenza

- Three types of influenza: A, B and C.
- Symptoms: fever, headache, dry cough, nasal congestion.
- Seasonal epidemic form: between 300k and 500k deaths globally every year.
- Pandemic form from zoonotic origins every 10-50 years: deaths in millions.



Avian Influenza

- Regular avian influenza outbreaks in poultry industry.
- Constant mutation: new strains (e.g. H10N3).
- Combination of avian influenza and human influenza can cause the next pandemic.




Antiviral drugs against influenza






- Antiviral drugs against influenza developed for human use.
- It is suggested that illegal use of antiviral drugs in farm causes development of drug-resistant influenza strains.
- Consequently: Chinese and US authorities (FDA) have banned use of certain antiviral drugs in poultry farms.
- Necessity of developing an analytical methodology to monitor antiviral drugs residue in poultry.

Existing methods

- Existing fast screening techniques.
- LC-MS/MS methods with very long/complicated procedures (SPE, two analytical columns) and/or not including all compounds of interest.
- Necessity to improve existing methods.
- Goal : develop a fast LC-MS/MS method including all relevant antiviral drugs against influenza.




Antiviral drugs selected



Antiviral drugs : properties

- Broad range of polarity: from highly polar to non-polar compound.
- Acid, basic and neutral compounds.
- Broad range makes analytical method challenging.



LC-MS/MS

- Method was developed on a LC-MS/MS instrument: Waters Acquity I-Class coupled with a Xevo TQ-XS.
- Provide suitable selectivity and sensitivity for confirmatory quantitative analysis of residue traces.




Mass Spectrometry optimisation

- Electrospray source of ionisation was compared to Unispray.
- Electrospray gave better sensitivity at the desired flow and chromatography mode
- Source parameters were optimised and most suitable MS transitions were selected.
- Positive mode and protonated molecules $[M+H]^+$ were chosen for this method




Chromatography: C18 columns

- Wide range of C18 columns experimented.
- Little to no retention for most polar compounds (Zanamivir, Ganciclovir, Ribavirin).
- Not adapted to polar analytes.




Chromatography: alternative to C18

- Alternative reversed-phase columns screened.
- Best retention for polar compounds: Selectra PFPP, better retention factor.
- Still very low retention, improved by use of ion pairing (HFBA) but was not practical.



Chromatography: HILIC



- HILIC is the best chromatography mode for polar compounds.
- Best results were found with columns driven by partitioning mechanism.
- BEH Amide (A) gave more appropriate retention to non-polar or neutral compounds than HILIC-Z (B).



Chromatography: ion suppression


- HILIC gave better ion suppression results than reversed-phase for polar compounds.
- Very high ion suppression zone around the dead time in reversed-phase mode.

Matrix effects



Sample preparation: sample extraction

- QuEChERS is widely used in drug residue food analysis but was found ineffective at extracting highly polar compounds.
- Acetonitrile, methanol and isopropanol were tried.
- Best compromise was found with [acetonitrile:water] 80:20 v:v, best overall extraction efficiencies (>40%) and relatively clean extracts.




Sample preparation: clean-up

- Various standard clean-up procedure were tested and found inefficient:
 - Ultrafiltration did not provide additional clean-up.
 - Freezing step trapped polar compounds in ice.
 - Several dspe sorbent were not beneficial.
- Dilute and shoot was chosen prior to LC-MS/MS analysis. Best final solvent mixture was [acetonitrile:methanol:water] 50:25:25 v:v:v.

Method performance: Validation

- Method was validated according to EU guidelines 2021/808.
- All criteria were validated.
- Reproducibility trueness were ranging from 84% to 127% and reproducibility precision from 2.8% to 22.7%.





Method performance: LOQ/LOD

- Eight matrix matched calibrants and the zero level were used to build a calibration curve, all R^2 were ≥ 0.988 .
- LOQ ranged from 0.03 to 10.46 $\mu\text{g}/\text{kg}$.

Analyte	Curve range ($\mu\text{g}/\text{kg}$)	LOD ($\mu\text{g}/\text{kg}$)	LOQ ($\mu\text{g}/\text{kg}$)
Arbidol Sulfoxyde	0.1 - 0.8	0.01	0.03
Arbidol	0.1 - 0.8	0.01	0.04
Arbitol Sulfone	0.5 - 4	0.11	0.35
Acyclovir	0.5 - 4	0.07	0.22
Rimantadine	0.5 - 4	0.03	0.11
Oseltamivir	0.5 - 4	0.05	0.18
Amantadine	1 - 8	0.06	0.19
Zanamivir	2 - 16	0.16	0.55
Peramivir	2 - 16	0.19	0.62
Ganciclovir	2 - 16	0.19	0.62
Viramidine	2 - 16	0.08	0.26
Oseltamivir Acid	2 - 16	0.28	0.92
Laninamivir	10 - 80	0.44	1.47
Ribavirin	25 - 200	2.48	8.26
Favipiravir	25 - 200	3.14	10.46

Occurrence in Irish market

- A total of 120 poultry products were selected from Irish market.
- Mix of EU/UK and outside UK/EU origin and mix of cooked and raw products.
- No trace of antiviral drug against influenza was found.



Conclusion

- LC-MS/MS method for the confirmatory and quantitative analysis of 15 antiviral drug residues in avian muscle.
- Fast and easy method.
- Method to monitor antiviral drug residues to better control the risk of resistant avian influenza strains generation.
- Sensitive method with LOQ ranging from 0.03 to 10.46 $\mu\text{g}/\text{kg}$.



Thank you for your attention
Any questions?



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 727864 and from the Chinese Ministry of Science and Technology (MOST).

Disclaimer: The content of this presentation does not reflect the official opinion of the European Commission and/or the Chinese government. Responsibility for the information and views expressed therein lies entirely with the author(s).